Top-News

Logic Devices News

Keine aktuellen Kursdaten verfügbar
WKN: 876991
ISIN: US5414021031
Typ: Aktie

Logic Devices News

17.05.22 - PR Newswire
LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference
LogicBio® Therapeutics to Present at H.C. Wainwright Global Investment Conference PR Newswire
16.05.22 - PR Newswire
LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates
LogicBio Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Business Updates PR Newswire
11.05.22 - PR Newswire
LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual Meeting
LogicBio Therapeutics Announces Upcoming Presentations on GeneRide Development Candidate and Multiple Advancements in AAV Manufacturing Processes at ASGCT Annual ...
09.05.22 - PR Newswire
Thinking about buying stock in LogicBio Therapeutics, Rivian Automotive, Lucid Group, Party City, or Nikola Corp?
Thinking about buying stock in LogicBio Therapeutics, Rivian Automotive, Lucid Group, Party City, or Nikola Corp? PR Newswire
09.05.22 - PR Newswire
LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia
LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia PR Newswire
23.03.22 - PR Newswire
LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference
LogicBio Therapeutics to Present at H.C. Wainwright Gene Therapy and Gene Editing Conference PR Newswire
08.03.22 - PR Newswire
LogicBio Therapeutics to Present at Barclays Global Healthcare Conference
LogicBio Therapeutics to Present at Barclays Global Healthcare Conference PR Newswire
04.03.22 - PR Newswire
LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates
LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates PR Newswire
02.02.22 - PR Newswire
LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program
LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program - Company to host conference call and webcast today at 8:30 a.m. ET PR Newswire
04.01.22 - PR Newswire
LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference
LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference PR Newswire
22.12.21 - PR Newswire
LogicBio Therapeutics Provides Business Updates
LogicBio Therapeutics Provides Business Updates - SUNRISE Phase 1/2 interim data expected to be announced in 2Q 2022 - - New GeneRide™ development candidate nominated ...
15.11.21 - PR Newswire
LogicBio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones
LogicBio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones - Early clinical results from SUNRISE trial demonstrated first-​ever ...
11.11.21 - PR Newswire
LogicBio Therapeutics to Participate in Upcoming Investor Conferences
LogicBio Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
12.10.21 - PR Newswire
LogicBio Therapeutics to Present New GeneRide™ Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
LogicBio Therapeutics to Present New GeneRide™ Data at the European Society of Gene and Cell Therapy Virtual Congress 2021 - Oral and poster presentations to highlight ...
24.09.21 - PR Newswire
LogicBio Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
LogicBio Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference PR Newswire
10.09.21 - PR Newswire
LogicBio Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
LogicBio Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire
08.07.21 - PR Newswire
LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021
LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021 PR Newswire
02.06.21 - PR Newswire
LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia
LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic ...
01.06.21 - PR Newswire
LogicBio Therapeutics to Participate in Upcoming Investor Conferences
LogicBio Therapeutics to Participate in Upcoming Investor Conferences PR Newswire
19.05.21 - PR Newswire
LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments
LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments - Stephen Boyer joined company as vice ...

Newssuche

Videos

09:30 Uhr
Technical Trading: Gold mit weiterem Potenzial
Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »